首页> 外文期刊>Journal of Clinical Oncology >Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
【24h】

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

机译:乳腺癌基质的分子解剖及其在雌激素受体阳性和阴性癌症中的预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The purpose of this study was to identify genes enriched in breast cancer stroma, assess the stromal gene expression differences between estrogen receptor (ER) -positive and -negative cancers, and separately determine their prognostic value in these two subtypes of breast cancers. METHODS: We compared gene expression profiles of pairs of fine-needle (stroma-poor) and core-needle (stroma-rich) biopsies from 37 cancers to identify stroma-associated genes. We defined stromal metagenes and tested their prognostic values in 684 node-negative patients who received no systemic adjuvant therapy and 259 tamoxifen-treated patients. RESULTS: We identified 293 probe sets overexpressed in core biopsies; these included five highly coexpressed gene clusters (metagenes) corresponding to immune functions and extracellular matrix components. These genes showed quantitative and qualitative differences between ER-positive and ER-negative cancers. A B-cell/plasma cell metagene showed strong prognostic value in ER-positive highly proliferative cancers, a lesser prognostic value in ER-negative cancers, and no prognostic value in ER-positive cancers with low proliferation. The hazard ratio for distant relapse in the lowest compared with the highest tertile of the pooled prognostic data set was 4.29 (95% CI, 2.04 to 9.01; P = .001) in ER-positive cancers and 3.34 (95% CI, 1.60 to 6.97; P = .001) in ER-negative cancers. This remained significant in multivariate analysis including routine variables and other genomic prognostic scores. As a result of quantitative differences in this metagene between ER-positive and ER-negative cancers, different thresholds apply in the two subgroups. Other stromal metagenes had inconsistent prognostic value. CONCLUSION: Among ER-negative and ER-positive highly proliferative cancers, a subset of tumors with high expression of a B-cell/plasma cell metagene carries a favorable prognosis.
机译:目的:本研究的目的是鉴定富含乳腺癌基质的基因,评估雌激素受体(ER)阳性和阴性癌症之间的基质基因表达差异,并分别确定其在这两种亚型乳腺癌中的预后价值。方法:我们比较了37种癌症的细针(贫基质)和芯针(富基质)活检对的基因表达谱,以鉴定与基质相关的基因。我们定义了间质元基因并在684例未接受全身辅助治疗的淋巴结阴性患者和259例他莫昔芬治疗的患者中测试了它们的预后价值。结果:我们确定了在核心活检组织中过表达的293个探针组。这些包括与免疫功能和细胞外基质成分相对应的五个高度共表达的基因簇(metagenes)。这些基因在ER阳性和ER阴性癌症之间显示出数量和质量上的差异。 B细胞/浆细胞元基因在ER阳性高度增生的癌症中具有较强的预后价值,在ER阴性癌症中的预后价值较低,而在增殖低的ER阳性癌症中无预后价值。在合并的预后数据集中,最低复发率与最高三分位数相比较,远距离复发的风险比在ER阳性癌症中为4.29(95%CI,2.04至9.01; P = .001)和3.34(95%CI,1.60至1.60)。 6.97; P = .001)在ER阴性癌症中。这在包括常规变量和其他基因组预后评分在内的多变量分析中仍然很重要。由于ER阳性和ER阴性癌症之间该基因的数量差异,两个亚组适用不同的阈值。其他基质间质基因的预后价值不一致。结论:在ER阴性和ER阳性的高度增生性癌症中,B细胞/浆细胞元基因高表达的部分肿瘤预后良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号